false
0001158780
0001158780
2026-08-26
2026-08-26
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
August 28, 2026 (August 26, 2026)
PLURI INC.
(Exact Name of Registrant as Specified in Its Charter)
| Nevada |
|
001-31392 |
|
98-0351734 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
| MATAM
Advanced Technology Park |
|
|
| Building No. 5 |
|
|
| Haifa, Israel |
|
3508409 |
| (Address of Principal Executive Offices) |
|
(Zip Code) |
011 972 74 710 7171
(Registrant’s telephone number, including
area code)
Not applicable
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
| Common Shares, par value $0.00001 per share |
|
PLUR |
|
The Nasdaq Capital Market |
Indicate by check mark whether the registrant
is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 Entry into a Material Definitive Agreement.
On August 26, 2026, Pluri Inc. (the “Company”)
entered into a securities purchase agreement (the “Purchase Agreement”) with a certain institutional investor (the “Purchaser”)
pursuant to which the Company agreed to issue and sell in a registered direct offering (the “Registered Direct Offering”)
registered under the Securities Act of 1933, as amended (the “Securities Act”), an aggregate of (i) 1,200,000 (the “Shares”)
of the Company’s common shares (“Common Shares”) and (ii) pre-funded warrants (the “Pre-Funded Warrants”)
to purchase up to 1,028,940 Common Shares (such shares issuable upon exercise of the Pre-Funded Warrants, the “Pre-Funded Warrant
Shares”, and together with the Shares and the Pre-Funded Warrants, the “Securities”). Each Share was offered
and sold at an offering price of $1.50 before deducting placement agent fees and other offering expenses, and each Pre-Funded Warrant was
offered and sold at an offering price of $1.49999 which is equal to the offering price per share less the $0.00001 exercise price of each Pre-Funded Warrant, before
deducting placement agent fees and other offering expenses.
Each Pre-Funded Warrant has
an initial exercise price per share of $0.00001, subject to certain adjustments. The Pre-Funded Warrants are
exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in
full.
Additionally, pursuant to the Purchase Agreement,
the Company agreed to issue to the Purchaser, in a concurrent private placement (the “Concurrent Private Placement” and, together
with the Registered Direct Offering, the “Offering”), common purchase warrants (the “Common Warrants”) to purchase
one Common Share for each Share or Pre-Funded Warrant purchased in the Registered Direct Offering for an aggregate of 2,228,940 Common
Shares. The Common Warrants will be initially exercisable six (6) months following their issuance and will be exercisable for a period
of five (5) years from the initial exercise date. The exercise price of the Common Warrants is $1.65 per share.
The Offering is expected to close on August 28,
2026. The net proceeds from the Offering are expected to be approximately $2,984,808, after deducting placement agent fees and other estimated
offering expenses. The Company intends to use the net proceeds from the Offering for corporate development and general purposes and working
capital.
In connection with the Offering, the Company entered
into a placement agency agreement (the “Placement Agency Agreement”) with A.G.P./Alliance Global Partners (the “Placement
Agent”), pursuant to which the Placement Agent agreed to serve as the Company’s sole placement agent in connection with the
Offering. As compensation for the services provided by the Placement Agent in connection with the Offering, the Company agreed to pay
the Placement Agent a cash fee of 6.50% of the gross proceeds which will be received by the Company from the sale of the securities at
the closing. The Company also agreed to reimburse the Placement Agent for certain of its out-of-pocket accountable expenses incurred in
connection with its services as placement agent in an amount not to exceed $50,000 in the aggregate.
The Securities were offered by the Company pursuant
to the Company’s shelf registration statement on Form S-3 (File No. 333-273347) declared effective by the Securities and Exchange
Commission (the “SEC”) on September 21, 2023 and the related prospectus supplement and accompanying prospectus.
Pursuant to the Purchase Agreement, the
Company agreed that: (A) for a period of 45 days after the closing date of the Offering, the Company will not (i) issue, enter into
any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents (as
defined in the Purchase Agreement) or (ii) file any registration statement or any amendment or supplement thereto, in each case
subject to certain limited exceptions; and (B) from the date of the Purchase Agreement and until six (6) month following the closing
date of the Offering, the Company will be prohibited from effecting or entering into an agreement to effect any issuance by the Company or any of
its subsidiaries of Common Shares or Common Share Equivalents (as defined in the Purchase Agreement) (or a combination of units
thereof) involving a Variable Rate Transaction (as defined in the Purchase Agreement), provided however, that the Company may enter into and/or issue Common Shares in an “at the market offering” with A.G.P./Alliance
Global Partners after 30 days following the closing date of the Offering.
The Purchase Agreement contains customary representations
and warranties, agreements and obligations, conditions to closing and termination provisions. In connection with the Offering, the Company’s
directors and executive officers also entered into lock-up agreements with the Company, pursuant to which such directors and officers
will not be permitted to, for a period of 45 days after the closing to offer, sell, contract to sell, hypothecate, pledge or otherwise
dispose of (or enter into any transaction which is designed to, or might reasonably be expected to, result in the disposition at any time,
including in the future (whether by actual disposition or effective economic disposition due to cash settlement or otherwise) by such
directors and officers or their affiliates), their Company securities, subject to certain limited exceptions.
The foregoing descriptions of the Common Warrants,
Pre-Funded Warrants, Purchase Agreement and Placement Agency Agreement do not purport to be complete and are qualified in their entirety
by reference to the full text of the Form of Common Warrant, Form of Pre-Funded Warrants, Form of Securities Purchase Agreement and Placement
Agency Agreement, which are attached as Exhibits 4.1, 4.2, 10.1 and 10.2, respectively, hereto and incorporated by reference herein.
The legal opinion of Sullivan & Worcester
LLP relating to the legality of the issuance and sale of the securities in the Registered Direct Offering is filed as Exhibit 5.1 to this
Current Report on Form 8-K.
Item 3.02 Unregistered Sales of Equity Securities.
Pursuant to the Concurrent Private Placement described
in Item 1.01 above, which description is incorporated into this Item 3.02 by reference, the Common Warrants (including the Common Stock
issuable upon exercise of the Common Warrants) (collectively, the “Private Securities”) were issued in reliance upon the exemption
from registration pursuant to Section 4(a)(2) under the Securities Act and Regulation D under the Securities Act, and corresponding provisions
of state securities or “blue sky” laws. The sale of the Private Securities did not involve a public offering and was made
without general solicitation or general advertising. Accordingly, the Private Securities have not been registered under the Securities
Act or any state securities laws and such securities may not be offered or sold in the United States absent registration, or an exemption
from registration, under the Securities Act and any applicable state securities laws.
Item 9.01 Financial Statements and Exhibits.
(d)
Exhibits
| Exhibit
No. |
|
Description |
| 4.1 |
|
Form of Common Warrant |
| 4.2 |
|
Form of Pre-Funded Warrant |
| 5.1 |
|
Legal opinion of Sullivan & Worcester LLP |
| 10.1 |
|
Form of Securities Purchase Agreement |
| 10.2 |
|
Placement Agency Agreement |
| 23.1 |
|
Consent of Sullivan & Worcester LLP (included in Exhibit 5.1) |
| 104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
PLURI INC. |
| |
|
| Date: August 28, 2026 |
By: |
/s/ Liat Zalts |
| |
Name: |
Liat Zalts |
| |
Title: |
Chief Financial Officer |
3